EAM
APLS

Eventide Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Eventide Asset Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-209,794
Closed -$8.05M – 181
2024
Q2 		$8.05M Hold
209,794
– – 0.14% 129
2024
Q1 		$12.3M Hold
209,794
– – 0.19% 113
2023
Q4 		$12.6M Buy
+209,794
New +$10.6M 0.21% 112
2023
Q3 		– Sell
-397,141
Closed -$36.2M – 157
2023
Q2 		$36.2M Sell
397,141
-97,859
-20% -$8.44M 0.61% 53
2023
Q1 		$32.7M Buy
495,000
+155,645
+46% +$8.98M 0.6% 57
2022
Q4 		$17.5M Hold
339,355
– – 0.35% 82
2022
Q3 		$23.2M Buy
+339,355
New +$20.1M 0.46% 68

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Eventide Asset Management's APLS Position: Q3 2024 in Review

Eventide Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q3 2024, closing a stake of 209,794 shares — an estimated $8.05M sold.

Eventide Asset Management first reported a position in APLS in Q3 2022 and held it in 7 quarters. The position peaked at $36.2M in Q2 2023. 265 funds tracked by Wall St. Rank hold APLS as of Q3 2024.

  • Eventide Asset Management reported no remaining Apellis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Eventide Asset Management sold 209,794 Apellis Pharmaceuticals shares in Q3 2024, an estimated $8.05M.
  • Eventide Asset Management first reported a position in Apellis Pharmaceuticals in Q3 2022 and held it in 7 quarters.
  • Eventide Asset Management's Apellis Pharmaceuticals position peaked at $36.2M in Q2 2023.
  • 265 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2024.

Based on Eventide Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.